Home / Peptides / MOTS-c: Status and What Human Research Exists
MOTS-c: Status and What Human Research Exists
MOTS-c is not FDA-approved; FDA found no clinical studies or human exposure data. What HHS's interim policy covers and what human studies actually measure.
On this page
Quick facts
Fact sheet
- U.S. status
- Strongest evidence
- Animal studies
- Status verified
MOTS-c is a peptide the body makes, and that fact is used to argue that an injected version must be fine. The research does not show that. The human studies measure the body’s own MOTS-c, not a treatment.
Key takeaways
- MOTS-c is not FDA-approved. FDA said it found no publicly available clinical studies or human exposure data for it.
- Human studies that mention MOTS-c measure the peptide the body makes; they did not give it as a treatment.
- HHS’s October 2026 interim policy covers certain compounded MOTS-c acetate by injection, under conditions. That is enforcement discretion, not FDA approval.
- Metabolic effects have been reported in mice and other lab models. Those results have not been shown in people.
- The trial HHS cites is of an analogue, which is a different molecule.
Is MOTS-c FDA-approved?
MOTS-c is not FDA-approved. FDA said it found no publicly available clinical studies or human exposure data for it, and no human pharmacokinetic data (FDA). A search of Drugs@FDA on Nov. 7, 2026 found no product listed as MOTS-c; that search shows approved products, not pending applications.
FDA’s drug center proposed in July 2026 not to list MOTS-c for compounding. The advisory committee voted 7–5–2 in favor of listing it, according to a law-firm account (secondary source). FDA’s page on substances that may present significant safety risks lists MOTS-c among nominations that were withdrawn, with a concern about immunogenicity and impurities. We did not find it in FDA’s 503A categories list.
What does HHS’s policy cover?
HHS’s October 2026 interim policy covers certain compounded MOTS-c acetate by injection, under conditions. That is enforcement discretion, not FDA approval. As we read the policy, it covers MOTS-c acetate, subcutaneous or intramuscular, as a single active ingredient, under its other conditions. For the 503A rules and what the policy does not do, see 503A compounding of peptides.
What do human studies of MOTS-c show?
Human studies that mention MOTS-c measure the peptide the body makes; they did not give it as a treatment. They report MOTS-c levels in blood, for example after exercise or in heat. A search of ClinicalTrials.gov on Nov. 7, 2026 found no trial in which MOTS-c was given as a treatment (search). The records it returns measure MOTS-c in blood, are unrelated to it, or are not real studies, and we do not count them.
This distinction matters because “the body makes it” is not the same as “an injected version has been tested.” Metabolic effects have been reported in mice and other lab models. Those results have not been shown in people, and we do not list them here.
What about the trial HHS cites?
HHS’s policy refers to a randomized trial of “a MOTS-c analogue” with no serious adverse events. An analogue is a different molecule, not MOTS-c, and HHS does not identify the trial in the text we read. The registry has an early-phase trial of an analogue called CB4211 (NCT03998514), completed in 2021 with no results posted, but we could not confirm it is the one HHS means, and we found no publication. We do not attribute its findings to MOTS-c.
Where do HHS and FDA disagree?
| Question | HHS (policy) | FDA (slides) |
|---|---|---|
| Safety evidence | “The available safety evidence points in one direction,” based on an analogue and rodent studies | No human data with MOTS-c |
| Historical use | Quantified, mostly as a single ingredient | Unknown; HHS’s data are not published in the text we read |
We present both and do not choose.
What are the risks?
- No clinical safety data. FDA says clinical and nonclinical safety information is missing, and it identified no published toxicity studies.
- Immune reactions. FDA names a concern with the injected route, made worse by aggregation and impurities.
- No reports is not reassurance. FDA’s adverse event system had no reports for MOTS-c, and FDA cautions that this does not imply the substance is without risk.
- Long-term risks are unknown.
- Sport. FDA notes that MOTS-c appears as prohibited in a global anti-doping database.
Which claims are not supported?
- “It copies the effects of exercise” or “it changes metabolism in people.” The reported effects are from mice and other lab models, not people.
- “The body makes it, so an injection is harmless.” The injected product has not been studied in people.
- “There is a human trial of MOTS-c.” The trial HHS cites is of an analogue, and the human studies we found measure blood levels.
- “HHS approved it.” The policy is enforcement discretion, not approval.
What should you ask your doctor?
- What is behind the concern that makes me interested in MOTS-c (weight, blood sugar, performance), and what evidence-based options exist?
- If it is suggested, what human evidence supports it for my goal, given that FDA found none?
- Is it a compounded product made under a patient-specific prescription, who made it, and does it contain one active ingredient?
- Do I compete in a tested sport?
We do not give doses, cycles or preparation instructions, and we do not recommend sellers. For MOTS-c next to other peptides marketed for aging, see our guide to peptides for longevity.
Frequently asked questions
Is MOTS-c FDA-approved?
No. MOTS-c is not FDA-approved. FDA said it found no publicly available clinical studies or human exposure data for it.
Has MOTS-c been tested in people?
Human studies that mention MOTS-c measure the peptide the body makes; they did not give it as a treatment.
Is MOTS-c covered by the HHS policy?
HHS’s October 2026 interim policy covers certain compounded MOTS-c acetate by injection, under conditions. That is enforcement discretion, not FDA approval.
Does MOTS-c work like exercise?
Metabolic effects have been reported in mice and other lab models. Those results have not been shown in people.
Is there a MOTS-c trial?
We found no trial in which MOTS-c was given as a treatment. The trial HHS cites is of an analogue, which is a different molecule.
From Best Peptides Today
Sources we checked
- FDA presentations to the Pharmacy Compounding Advisory Committee on MOTS-c (July 23, 2026)FDA. Accessed .
- FDA briefing document on MOTS-cFDA. Accessed .
- FDA CDER proposal on seven peptides (July 2026)FDA. Accessed .
- FDA: bulk drug substances that may present significant safety risks (Category 2)FDA. Accessed .
- FDA: bulk drug substances nominated under section 503A, by category (updated May 14, 2026)FDA. Accessed .
- Drugs@FDA (searched Nov. 7, 2026; no product listed as MOTS-c)FDA. Accessed .
- Federal Register: HHS enforcement discretion policy on 503A peptide compounding (Oct. 30, 2026)Other. Accessed .
- HHS: Enforcement Discretion Policy, with Appendices A and BOther. Accessed .
- McDermott+: PCAC votes on peptides (secondary source)Other. Accessed .
- Blood MOTS-c levels in response to exercise, 2021 (PubMed)PubMed. Accessed .
- Blood MOTS-c levels in response to heat, 2025 (PubMed)PubMed. Accessed .
- ClinicalTrials.gov search for MOTS-c (searched Nov. 7, 2026)ClinicalTrials.gov. Accessed .
- ClinicalTrials.gov NCT03998514 (CB4211, a MOTS-c analogue, phase 1a/1b)ClinicalTrials.gov. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.